Cellectis to participate in upcoming investor conferences
Cellectis said it will participate in upcoming investor conferences. The Company is listed on Euronext Growth under ALCLS and on NASDAQ as CLLS.
NEW YORK, Sept.
01, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming…